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CASE REPORT
diffuse Large cell Lymphoma Presenting as a
Sacral Mass and Lupus Anticoagulant
Lilangi S. Ediriwickrema, MSa*, and Wajih Zaheer, MDb
aYale School of Medicine, New Haven, Connecticut; bMedical Oncology & Hematology,
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A 67-year-old gentleman presented to Yale-New Haven Hospital (YNHH†) for assessment
of a supratherapeutic INR and sacral lesion. Hematologic workup revealed elevated ESR,
PT, INR, PTT, and CRP, mixing studies that failed to correct, and a positive Russell Viper
Venom Test (RVVT), which confirmed the presence of lupus anticoagulant (LA), a subtype
of antiphospholipid syndrome (APA). Pathology of the patient’s sacral lesion revealed diffuse
large B-cell lymphoma. This case provides insight into the association between APA and
lymphoid neoplasm. The patient’s unique presentation is in marked contrast to other reports
of APA and lymphoid malignancy, which are typically associated with elevated PTT, normal
PT, minimal extranodal disease, and potential thrombotic complications. Further, treatment
with Rituximab-CHOP chemotherapy led to excellent clinical response with tumor remission
and normalization of PT and PTT. 
IntroductIon
While  antiphospholipid  syndrome
(APA) exhibits a strong association with
several autoimmune disorders, it is rela-
tively uncommon to find individuals with
both APA and lymphoid-derived neoplasm.
Clinically, APA and associated thrombotic
events are typically correlated with solid
tumor malignancies. However, there have
been several case reports positing a rela-
tionship  between  antiphospholipid  anti-
bodies and lymphoproliferative diseases,
which may be due to APA production by
malignant B cells or by B cells that are ac-
tivated via cytokine secretion by malignant
T cells [1]. 
*To whom all correspondence should be addressed: Lilangi Ediriwickrema, Yale School of
Medicine, 367 Cedar Street, New Haven, CT 06510; E-mail: lilangi.ediriwickrema@yale.edu.
†Abbreviations: YNHH, Yale-New Haven Hospital; PT, prothrombin; PTT, partial thrombo-
plastin time; LA, lupus anticoagulant; APA, antiphospholipid syndrome; R-CHOP, ritux-
imab-cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone/prednisolone;
NHL, non-Hodgkin lymphoma; RVVT, Russell Viper Venom Time.
Keywords: coagulopathy, diffuse large cell lymphoma, lupus anticoagulant, antiphospho-
lipid syndrome, sacral lesion, R-CHOP, supratherapeutic INRcASe PreSentAtIon
A 67-year-old gentleman was seen at
Yale-New Haven Hospital (YNHH) for as-
sessment  of  a  supratherapeutic  INR  and
sacral lesion. The patient had been well until
approximately 6 months prior, when he de-
veloped right leg pain following an episode
of intermittent fevers and a sledding injury.
The patient was subsequently worked up for
sciatica, which led to the discovery of a sacral
lesion on imaging. Pre-operative assessment
prior to biopsy led to an incidental discovery
of a supratherapeutic INR of 8.41, in addition
to elevated ESR, PT, INR, PTT, and CRP (see
Table 1). At YNHH, the physical examination
was notable for mild hepatosplenomegaly,
decreased right plantar-flexion (tibial nerve,
S1-S2), pain with right knee flexion (sciatic
nerve, L5-S2), and a 1+ right patellar reflex
(L4).  The  patient  also  presented  with  a
smooth sacral target-like lesion, 7.5 cm in di-
ameter with blurry outlines, over the area of
biopsy for which he was subsequently treated
with doxycycline and hydrocortisone given a
recent history of multiple tick bites.  
Of note, the patient reported lethargy,
intermittent low grade fevers, and a 12- to
15-pound  weight  loss  over  the  past  6
months. He claimed to bruise and bleed eas-
ily  while  on  aspirin.  The  patient  denied
Coumadin  use,  night  sweats,  back  pain,
chills, headaches, swollen lymph nodes or
joints,  dark  or  bloody  urine,  black  tarry
stools, jaundice, or recent changes in diet.
Recent medication use included coenzyme
Q10,  and  current  medications  included
Losartan, HCTZ, and Centrum silver multi-
vitamin. He has no known drug allergies.
dIScuSSIon
Differential Diagnosis
The patient presented with a suprather-
apeutic INR, as well as significantly elevated
PT and PTT levels. The patient noticed in-
creased bruising and bleeding in the past sev-
eral years, which coincided with the use of
aspirin and coenzyme Q10. Importantly, sal-
icylic acid inhibits prostaglandin and throm-
boxane  synthesis,  which  deters  platelet
aggregation. Furthermore, coenzyme Q10 is
a lipid soluble antioxidant, which has been
proposed to increase bleeding time and de-
crease blood pressure [2]. The patient also re-
cently  took  doxycycline  for  a  target-like
lesion due to Lyme disease. Antibiotics can
change gut flora and decrease Vitamin K
synthesis, potentially affecting the rate of
gamma carboxylation of Factors II, V, VII,
and X of the clotting cascade.   
Overall, when assessing coagulopathies,
it is helpful to consider inherited versus ac-
quired etiologies as explored in Table 2. Our
patient had late-onset, acute elevations of PT
and  PTT,  making  inherited  disorders  less
likely. Possible etiologies on initial assessment
include DIC, liver disease, or inhibitors of fib-
rinogen, factor II, V or X. The patient did not
exhibit any signs of active bleeding and had a
normal platelet count, making DIC less likely.
Further, the patient did not manifest symptoms
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table 1. Serum Analysis
Variable
WBC (per mm3)
Platelets (per mm3)
AST (U/L)
ALT (U/L)
Bilirubin (mg/dL)
Albumin (g/dL)
ESR (mm/hr)
PT (sec)
INR
PTT (sec)
CRP (mg/L)
reference range
4,500-11,000
150,000-350,000
8-20
8-20
0.1-1.0
3.5-5
1-14 (males)
10.3-13.2
0.8-1.2
22.1-34.0
<10
Patient’s Value
8,600
260,000
19
12
0.47
3.5
22
86.2
8.41
66.3
58.6of infection or shock. Liver disease is similarly
unlikely since the patient had normal LFTs, al-
kaline phosphatase, bilirubin, and albumin lev-
els. Consequently, the most likely etiology is
either a factor inhibitor or antiphospholipid an-
tibody, the latter of which typically presents
with only elevated PTT levels [3].
Pathological Discussion
Diagnostic workup consisted of mixing
studies, Russell Viper Venom Time (RVVT)
and  serum  analysis  of  factor  levels,  von
Willebrand factor antigen, and Ristocetin
Cofactor antigen. The results of each test are
reported in Tables 3 and 4. While the workup
for von Willebrand disease and Hemophilia
A were noncontributory, the mixing studies
and RVVT were particularly helpful.  
A mixing study helps to differentiate be-
tween factor deficiency and inhibition. Our
patient’s plasma was mixed at a 1:1 ratio
with normal plasma. However, the PT and
PTT values failed to normalize and remained
elevated, indicating the role of a factor in-
hibitor. Inhibitors are commonly associated
with hemophilia, lymphoproliferative disor-
ders and other malignancies, autoimmune
disease, and the post-partum state. 
The RVVT utilizes the clotting cascade;
specifically, venom coagulant activates fac-
tor  X,  which  facilitates  the  formation  of
thrombin from prothrombin in the presence
of factor V and phospholipid. In the RVVT,
the concentration of viper venom and phos-
pholipid are rate-limiting. Lupus anticoagu-
lant interferes with the clotting cascade by
interacting with in vitro phospholipids, and
thereby prolongs the clotting time. With the
confirmatory RVVT test, excessive phos-
pholipid is added to the assay and the clot-
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table 2. Inherited vs. Aquired coagulopathies
Pt
ₑ
ₔ
ₑ
Ptt
ₔ
ₑ
ₑ
Inherited
Factor VII deficiency
Hemophilias, von Willebrand disease
Fibrinogen, Factor II, or V deficiency
Acquired
Vitamin K deficiency, liver disease,
and factor VII inhibitor
Factor inhibitors, antiphospholipid
antibody
Disseminated intravascular coagulation,
liver disease, and fibrinogen, Factor II,
V, or X inhibitor
table 3. Serum Factor Analysis
Factor
II
V
VII
X
Patient’s Level
118%
120%
43%
60%
normal range
50-150%
50-150%
50-150%
50-150%
table 4. coagulopathy diagnostic results
test
PTT Mixing Study 0’
PTT Mixing Study 60’
PT Mixing Study 0’
PT Mixing Study 60’
Russell Viper Venom Time
von Willebrand Factor Antigen
Ristocetin Cofactor
Factor VIII
time
51.0 seconds
60.7 seconds
50.5 seconds
48.0 seconds
2.52 
159%
187%
99%
normal
-
-
-
-
0-1.2
50-150%
50-150%
50-200%ting time is measured. After normalizing the
assay and confirmatory test, it is then possi-
ble to determine a ratio of clotting time with-
out phospholipid excess to with phospholipid
excess. Our patient’s ratio was significantly
greater than the normal range of 0-1.2, indi-
cating the presence of lupus anticoagulant
(LA) [4].
Lupus Anticoagulant
Lupus anticoagulant, as stated, is de-
tected based upon prolonged clotting times
on assay. However, LA causes thromboem-
bolism in vivo. The current understanding is
that while LA interferes with both coagula-
tion and anticoagulation, cell membranes in
vivo are postulated to create an environment
of net inhibition of anticoagulant pathways
to consequently promote thrombosis. The
three prevailing hypotheses for the mecha-
nism of action include activation of endothe-
lial  cells,  oxidant-mediated  injury  of  the
vascular endothelium via oxidized LDLs,
and interference of the regulatory functions
of prothrombin, protein C, tissue factor, and
other regulators of coagulation. Typically, di-
agnosis of LA requires meeting one of two
vascular criteria, including vascular throm-
bosis or obstetrics complication, and at least
one of two laboratory criteria of either anti-
cardiolipin antibodies or lupus anticoagulant
antibodies.  The  differential  diagnosis  for
thrombotic disorders, in general, includes but
is not limited to heparin-induced thrombo-
cytopenia, homocysteinemia, myeloprolifer-
ative disorders, and hyperviscosity. Patients
with APA who have concomitant risk factors,
including venous or arterial bed stasis or in-
jury, atherosclerosis risk factors, and oral
contraceptive use, exhibit an increased risk
of thromboses. In rare cases, patients may
present with multiple vascular occlusions
that result in death or a pulmonary embolism
following a venous thrombosis [5].
Diagnosis and Treatment
Biopsy and pathological assessment of
the patient’s sacral lesion revealed diffuse
large B-cell lymphoma. Standard therapy
consisting of Rituximab-CHOP chemother-
apy (cyclophosphamide, hydroxydaunoru-
bicin, oncovin, and prednisone) led to com-
plete response, as well as normalization of
PT and PTT.
Rituximab is a chimeric monoclonal an-
tibody that targets the CD20 antigen found
on the surface of both normal and malignant
B lymphocytes. CD20 is expressed on more
than 90 percent of B cell non-Hodgkin lym-
phomas (NHL) and is thought to interact
with rituximab to promote complement and
antibody-dependent cytotoxicity, as well as
apoptosis.  A  critical  trial  revealed  the
strengths of treating patients with rituximab
with CHOP versus CHOP alone with event-
free survival at 2 years at 57 percent versus
38 percent (p < 0.001), overall survival after
2 years at 70 percent versus 57 percent (p <
0.01), and a complete response rate at 76
percent versus 63 percent (p < 0.01). R-
CHOP, therefore, is an important treatment
modality for B-cell malignancies, further
supported by a decrease in reported adverse
effects such as neutropenia and infections
[6]. Rituximab also has been shown to be ef-
ficacious in treating a patient with APA and
SLE  who  presented  with  significant
thrombo-embolic events. Interestingly, long-
term clinical remission was associated with
the concomitant disappearance of lupus an-
ticoagulant after 2 months of treatment with
rituximab. Fewer consistent changes were
noted for serum levels of anticardiolipin and
B2GP1 [7]. 
Antiphospholipid  Syndrome  and  non-
Hodgkin Lymphoma
While antiphospholipid syndrome ex-
hibits a strong association with several au-
toimmune disorders such as systemic lupus
erythematosus (SLE), it is relatively un-
common to find individuals with both APA
and lymphoid-derived neoplasm. Clinically,
APA and associated thrombotic events are
typically correlated with solid tumor malig-
nancies. However, there have been several
case reports positing a relationship between
antiphospholipid  antibodies  and  lympho-
proliferative diseases, which may be due to
APA production by malignant B cells or by
B cells that are activated via cytokine secre-
tion by malignant T cells [1]. Several studies
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and non-Hodgkin lymphoma. In one study
of 90 NHL patients, 24 (26.6 percent) were
identified to have elevated serum APA. In-
terestingly, lymphoma-induced vessel com-
pression was the most common cause of clot
formation in these NHL patients. Moreover,
APA positive patients with elevated anticar-
diolipin antibodies and anti-ʲ2-glycopro-
tein-I  antibodies  were  followed  for  14
months  without  a  single  occurrence  of
thromboembolism. Elevated APA was de-
tected more frequently in women and the
elderly and was not correlated with the his-
tology or stage of the lymphoma. Twelve of
24 patients (50 percent) had diffuse large B-
cell lymphoma, as diagnosed in our patient
[8].  
However, a case report from Italy de-
scribes a patient with an APA positive pe-
ripheral T  cell  lymphoma  that  presented
with deep venous thrombosis (DVT) [1].
Another Italian group reports a statistically
significant association between antiphos-
pholipid antibodies and lymphomas after
correcting for age, sex, type, and stage of
lymphoma, as well as supports the use of
APA to identify lymphoma patients who are
at increased risk to develop thrombotic com-
plications. The study reveals that 5.1 percent
of sampled APA-positive patients develop
thromboses annually, compared to 0.75 per-
cent of APA-negative patients. The Italian
group did not find APA to be a useful pre-
dictor of treatment outcome or overall prog-
nosis [9].
Yet a more recent study claims that APA
may play a role as a prognostic marker in
NHL. In 2006, the study revealed 41 percent
of NHL patients (35/86 patients) to have el-
evated APA at diagnosis. The patients had a
statistically significant, shorter 2-year sur-
vival time at 63 +/- 11 percent, compared to
90 +/- 5 percent for patients without APA at
diagnosis. The study did not find a correla-
tion  between APA  and  age,  sex,  disease
state, grade, progression, performance sta-
tus, treatment choice, or response to treat-
ment [10].
Another analysis consisting of 22 NHL
patients, of whom nine (40.9 percent) were
positive for elevated APA, were assessed for
response to treatment. Interestingly, all pa-
tients who responded to treatment exhibited
normalization of their APA titers, while non-
responders  retained  elevated  APA  levels
[11]. Though various treatment modalities
have been attempted, the use of R-CHOP
has been shown to be effective in treating
several patients with APA-positive large B-
cell lymphoma via published case reports
[12-13]. Further, one case report describes
the development of systemic thromboses de-
spite radiologically proven resolution of a
lymphoma upon treatment with only CHOP
chemotherapy without rituximab [14].
concLuSIon
This report describes the presentation of
large-cell lymphoma and acquired lupus anti-
coagulant as a lower extremity pain following
a recent sledding injury and provides insight
into the association between APA and lym-
phoid neoplasm. The patient in this vignette
presented with a sacral mass and elevated PT
and PTT levels and was ultimately diagnosed
with diffuse large B-cell lymphoma. Interest-
ingly, the patient’s tumor was early stage with
extranodal disease. The patient did not sustain
any thrombotic events and underwent a sacral
biopsy and porta-catheter placement without
bleeding.  This  unique  presentation  is  in
marked contrast to other reports of APA and
lymphoid malignancy, which are typically as-
sociated with elevated PTT, normal PT, min-
imal  extranodal  disease,  and  potential
thrombotic complications [1,3,5,9,10]. Fur-
ther, treatment with R-CHOP led to excellent
clinical response with tumor remission and
normalization of PT and PTT. A PET scan
confirmed  complete  response  to  R-CHOP
prior to consolidation with radiation therapy
at a time point corresponding with the disap-
pearance of APA levels, thereby indicating a
correlation between APA and lymphoid neo-
plasm. Overall, it would be interesting to fur-
ther explore the role of rituximab in treating
APA as it is unclear whether the drug acts di-
rectly on APA, elicits an indirect response by
treating an underlying malignancy, or pro-
motes a combination of both mechanisms.
437 Ediriwickrema and Zaheer: Lymphoma presenting as lupus anticoagulantreFerenceS
1. Onida P, Tresoldi M, Rugarli C. Anti-phos-
pholipid-antibody syndrome associated with
peripheral T-cell lymphoma. A J Hematol.
1997;55(3):167-8.
2. Combs AB, Porter TH, Folkers K. Anticoag-
ulant Activity of Naphthoquinone Analog of
Vitamin K and an Inhibitor of Coenzyme
Q10-Enzyme Systems. Res Commun Chem
Pathol Pharmacol. 1976;13(1):109-14. 
3. Moore GW, Kamat AV, Gurney DA, O’Con-
nor O, Rangarajan S, Carr R, et al. Case Re-
port: Alteration in the laboratory profile of a
lupus anticoagulant in a patient with non-
Hodgkin’s lymphoma. Clinical Laboratory
Hematology. 2004;26(6):429-34.
4. Zehnder J. Clinical use of Coagulation Tests.
UpToDate.com [Internet]. c2011 [updated 2011
Apr 28; cited 2011 Sept 6]. Available from:
http://www.uptodate.com/contents/clinical-use-
of-coagulation-tests.
5. Levine JS, Branch DW, Rauch J. The an-
tiphospholipid  syndrome.  N  Engl  J  Med.
2002;346(10):752-63.
6. Plosker GL, Figgitt DP. Rituximab: a review
of its use in non-Hodgkin’s lymphoma and
chronic  lymphocytic  leukemia.  Drugs.
2003;63(8):803-43.
7. Ahn ER, Lander G, Bidot CJ, Jy W, Ahn YS.
Long term remission from life-threatening
hypercoagulable state associated with lupus
anticoagulant (LA) following rituximab ther-
apy. Am J Hematol. 2005;78(2):127-9.
8. Genvresse I, L￼ftner D, Sp￤th-Schwalbe E,
Buttgereit F. Prevalence and clinical signifi-
cance of anticardiolipin and anti-ʲ2-glyco-
protein-I  antibodies  in  patients  with  non-
Hodgkin’s  lymphoma.  Eur  J  Haematol.
2002;68(2):84-90.
9. Pusterla S, Previtali S, Marziali S, Cortelazzo
S, Rossi A, Barbui T, et al. Antiphospholipid
antibodies in lymphoma: prevalence and clin-
ical significance. Hematol J. 2004;5(4):341-6. 
10. Bairey O, Blickstein D, Monselise Y, Lahav
J, Stark P, Prokocimer M, et al. Antiphos-
pholipid antibodies may be a new prognostic
parameter in aggressive non-Hodgkin’s lym-
phoma. Eur J Haematol. 2006;76(5):384-91.
11. Sciarra A, Stasi R, Stipa E, Masi M, Oliva F,
Olivieri M, et al. Antiphospholipid antibodies:
their prevalence, clinical significance and cor-
relation with cytokine levels in acute myeloid
leukemia and non-Hodgkin’s lymphoma. Re-
cent Progress in Medicine. 1995;86(2):57-62.
12. Simon Z, Tarr T, Ress Z, Gergely L, Kiss E,
Illes A. Successful rituximab-CHOP treatment
of systemic lupus erythematosus associated
with diffuse large B-cell non-Hodgkin lym-
phoma. Rheumatology. 2007;28(2):179-83.  
13. Veneri D, Ambrosetti A, Franchini M, Mosna
F, Poli G, Pizzolo G. Remission of severe an-
tiphospholipid syndrome associated with non-
Hodgkin’s B-cell lymphoma after combined
treatment with rituximab and chemotherapy.
Haematologica. 2005;90(10):104-5.
14. Keung YK, Cobos E, Meyerrose GE, Rober-
son GH. Progressive thrombosis after treat-
ment  of  diffuse  large  cell  non-Hodgkin’s
lymphoma and concomitant lupus anticoagu-
lant. Leukemia and Lymphoma. 1996;20(3-
4):341-5. 
438 Ediriwickrema and Zaheer: Lymphoma presenting as lupus anticoagulant